{"id":25315,"date":"2022-08-09T05:08:20","date_gmt":"2022-08-09T05:08:20","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=96157"},"modified":"2022-08-09T05:08:20","modified_gmt":"2022-08-09T05:08:20","slug":"nyxoah-reports-second-quarter-and-first-half-2022-financial-and-operating-results","status":"publish","type":"post","link":"https:\/\/myanmarnewswire.com\/nyxoah-reports-second-quarter-and-first-half-2022-financial-and-operating-results\/","title":{"rendered":"Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results"},"content":{"rendered":"
REGULATED INFORMATION<\/strong><\/p>\n Nyxoah Reports Second Quarter and First Half 2022 Financial and Operating Results<\/strong><\/p>\n DREAM enrollment complete, 12-month clinical data expected in fall of 2023<\/em><\/p>\n Mont-Saint-Guibert, Belgium \u2013 August 8, 2022, 10:05pm\u00a0CET \/ 4:05pm\u00a0ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)\u00a0<\/strong>(\u201cNyxoah\u201d or the \u201cCompany\u201d), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the second quarter and first half of 2022.<\/p>\n Second Quarter 2022 Financial and Operating Highlights<\/strong><\/p>\n \u201cWe made significant progress on all of our key strategic priorities this quarter, including activating 11 new commercial sites in Germany, completing enrollment in our DREAM trial, and receiving approval for our ACCCESS IDE,\u201d commented Olivier Taelman, Nyxoah\u2019s Chief Executive Officer. \u201cFrom a commercial standpoint, our second quarter performance showing 42% quarter-over-quarter growth strengthens our confidence that we will achieve market leadership status in Germany by the end of 2022.\u201d<\/p>\n \u201cAs the only commercially available hypoglossal nerve stimulation (HGNS) therapy approved for the treatment of CCC patients, we are encouraged by the first strong results from patients who are six months post-implantation. These results, combined with no longer having to perform a drug-induced sleep endoscopy (DISE) procedure prior to implant, are driving physicians to recommend Genio for their CCC and non-CCC patients,\u201d continued Mr. Taelman.<\/p>\n Mr. Taelman concluded, \u201cIn the meantime, we have already begun investing in our U.S. market access organization. As for our ACCCESS study, we expect to implant the first patients before year end.\u201d<\/p>\n Second Quarter and First Half 2022 Results<\/strong><\/p>\n UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION \u2013 INTERIM CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS\u00a0FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30,\u00a02022\u00a0(in thousands)<\/strong><\/p>\n <\/p>\n \u00a0UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION \u2013 INTERIM CONSOLIDATED STATEMENT OF FINANCIAL POSITION\u00a0AS AT JUNE 30, 2022 (in thousands)<\/strong><\/p>\n\n
\n\n
\n <\/td>\n For the three months ended June 30<\/strong><\/td>\n <\/td>\n For the six months ended June 30<\/strong><\/td>\n <\/td>\n<\/tr>\n \n <\/td>\n 2022<\/strong><\/td>\n 2021<\/strong><\/td>\n <\/td>\n 2022<\/strong><\/td>\n 2021<\/strong><\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n Revenue<\/td>\n \u20ac 935<\/td>\n \u20ac 170<\/td>\n <\/td>\n \u20ac 1\u00a0595<\/td>\n \u20ac 355<\/td>\n<\/tr>\n \n Cost of goods sold<\/td>\n (\u20ac 334)<\/td>\n (\u20ac 63)<\/td>\n <\/td>\n (\u20ac 623)<\/td>\n (\u20ac 115)<\/td>\n<\/tr>\n \n Gross profit<\/strong><\/td>\n \u20ac 601\u00a0<\/strong><\/td>\n \u20ac 107\u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u20ac 972\u00a0<\/strong><\/td>\n \u20ac 240\u00a0<\/strong><\/td>\n<\/tr>\n \n Research and Development Expense<\/td>\n (\u20ac 3\u00a0470)<\/td>\n (\u20ac 2\u00a0398)<\/td>\n <\/td>\n (\u20ac 7\u00a0065)<\/td>\n (\u20ac 5\u00a0492)<\/td>\n<\/tr>\n \n Selling, General and Administrative Expense<\/td>\n (\u20ac 4\u00a0536)<\/td>\n (\u20ac 3\u00a0913)<\/td>\n <\/td>\n (\u20ac 8\u00a0729)<\/td>\n (\u20ac 6\u00a0279)<\/td>\n<\/tr>\n \n Other income\/(expense)<\/td>\n \u20ac 14<\/td>\n (\u20ac 101)<\/td>\n <\/td>\n \u20ac 150<\/td>\n (\u20ac 97)<\/td>\n<\/tr>\n \n Operating loss for the period<\/strong><\/td>\n (\u20ac 7\u00a0391)<\/strong><\/td>\n (\u20ac 6\u00a0305)<\/strong><\/td>\n <\/td>\n (\u20ac 14\u00a0672)<\/strong><\/td>\n (\u20ac 11\u00a0628)<\/strong><\/td>\n<\/tr>\n \n Financial income<\/td>\n \u20ac 4\u00a0670<\/td>\n \u20ac 39<\/td>\n <\/td>\n \u20ac 6\u00a0246<\/td>\n \u20ac 43<\/td>\n<\/tr>\n \n Financial expense<\/td>\n (\u20ac 2\u00a0162)<\/td>\n (\u20ac 574)<\/td>\n <\/td>\n (\u20ac 2\u00a0950)<\/td>\n (\u20ac 899)<\/td>\n<\/tr>\n \n Loss for the period before taxes<\/strong><\/td>\n (\u20ac 4\u00a0883)<\/strong><\/td>\n (\u20ac 6\u00a0840)<\/strong><\/td>\n <\/td>\n (\u20ac 11\u00a0376)<\/strong><\/td>\n (\u20ac 12\u00a0484)<\/strong><\/td>\n<\/tr>\n \n Income taxes<\/td>\n (\u20ac 107)<\/td>\n (\u20ac 99)<\/td>\n <\/td>\n (\u20ac 315)<\/td>\n (\u20ac 124)<\/td>\n<\/tr>\n \n Loss for the period<\/strong><\/td>\n (\u20ac 4\u00a0990)<\/strong><\/td>\n (\u20ac 6\u00a0939)<\/strong><\/td>\n <\/td>\n (\u20ac 11\u00a0691)<\/strong><\/td>\n (\u20ac 12\u00a0608)<\/strong><\/td>\n<\/tr>\n \n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n<\/tr>\n \n Loss attributable to equity holders<\/strong><\/td>\n (\u20ac 4\u00a0990)<\/strong><\/td>\n (\u20ac 6\u00a0939)<\/strong><\/td>\n <\/td>\n (\u20ac 11\u00a0691)<\/strong><\/td>\n (\u20ac 12\u00a0608)<\/strong><\/td>\n<\/tr>\n \n Other comprehensive loss<\/strong><\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n Items that may be subsequently reclassified to profit or loss (net of tax)<\/strong><\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n Currency translation differences<\/td>\n (\u20ac 12)<\/td>\n \u20ac 262<\/td>\n <\/td>\n (\u20ac 114)<\/td>\n \u20ac 192<\/td>\n<\/tr>\n \n Total comprehensive loss for the year, net of tax<\/strong><\/td>\n (\u20ac 5\u00a0002)<\/strong><\/td>\n (\u20ac 6\u00a0677)<\/strong><\/td>\n <\/td>\n (\u20ac 11\u00a0805)<\/strong><\/td>\n (\u20ac 12\u00a0416)<\/strong><\/td>\n<\/tr>\n \n Loss attributable to equity holders<\/strong><\/td>\n (\u20ac 5\u00a0002)<\/strong><\/td>\n (\u20ac 6\u00a0677)<\/strong><\/td>\n <\/td>\n (\u20ac 11\u00a0805)<\/strong><\/td>\n (\u20ac 12\u00a0416)<\/strong><\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n Basic Loss Per Share (in EUR)<\/strong><\/td>\n (\u20ac 0,193)<\/strong><\/td>\n (\u20ac 0,314)<\/strong><\/td>\n <\/td>\n (\u20ac 0,453)<\/strong><\/td>\n (\u20ac 0,570)<\/strong><\/td>\n<\/tr>\n \n Diluted Loss Per Share (in EUR)<\/strong><\/td>\n (\u20ac 0,193)<\/strong><\/td>\n (\u20ac 0,314)<\/strong><\/td>\n <\/td>\n (\u20ac 0,453)<\/strong><\/td>\n (\u20ac 0,570)<\/strong><\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n \n\n
\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n As at<\/strong><\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n <\/td>\n June 30<\/strong>
\n\u00a02022<\/strong><\/td>\n\u00a0<\/strong><\/td>\n December 31 2021<\/strong><\/td>\n<\/tr>\n \n ASSETS<\/strong><\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n Non-current assets<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n<\/tr>\n \n Property, plant and equipment<\/td>\n <\/td>\n <\/td>\n \u20ac 2 111<\/td>\n <\/td>\n \u20ac 2 020<\/td>\n<\/tr>\n \n Intangible assets<\/td>\n <\/td>\n <\/td>\n 32 570<\/td>\n \u00a0<\/strong><\/td>\n 25 322<\/td>\n<\/tr>\n \n Right of use assets<\/td>\n <\/td>\n <\/td>\n 3 410<\/td>\n <\/td>\n 3 218<\/td>\n<\/tr>\n \n Deferred tax asset<\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n 1 429<\/td>\n \u00a0<\/strong><\/td>\n 46<\/td>\n<\/tr>\n \n Other long-term receivables<\/td>\n <\/td>\n <\/td>\n 180<\/td>\n <\/td>\n 164<\/td>\n<\/tr>\n \n <\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u20ac 39 700<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u20ac 30 770<\/strong><\/td>\n<\/tr>\n \n Current assets<\/strong><\/td>\n <\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n<\/tr>\n \n Inventory<\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n 506<\/td>\n \u00a0<\/strong><\/td>\n 346<\/td>\n<\/tr>\n \n Trade receivables<\/td>\n <\/td>\n <\/td>\n 957<\/td>\n <\/td>\n 226<\/td>\n<\/tr>\n \n Other receivables<\/td>\n \u00a0<\/strong><\/td>\n \u00a0<\/strong><\/td>\n 1 548<\/td>\n \u00a0<\/strong><\/td>\n 2 286<\/td>\n<\/tr>\n \n Other current assets<\/td>\n <\/td>\n <\/td>\n 852<\/td>\n <\/td>\n 1 693<\/td>\n<\/tr>\n \n Financial assets<\/td>\n <\/td>\n <\/td>\n 47 717<\/td>\n <\/td>\n \u2212<\/td>\n<\/tr>\n \n Cash and cash equivalents<\/td>\n <\/td>\n <\/td>\n 75 602<\/td>\n <\/td>\n 135 509<\/td>\n<\/tr>\n \n \u00a0<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac 127 182<\/strong><\/td>\n <\/td>\n \u20ac 140 060<\/strong><\/td>\n<\/tr>\n \n Total assets<\/strong><\/td>\n <\/td>\n <\/td>\n \u20ac 166 882<\/strong><\/td>\n <\/td>\n \u20ac 170 830<\/strong><\/td>\n<\/tr>\n \n <\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n \u00a0<\/strong><\/td>\n <\/td>\n<\/tr>\n \n EQUITY AND LIABILITIES<\/strong><\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n <\/td>\n<\/tr>\n \n